Swedish Orphan Biovitrum AB ( (SE:SOBI) ) has shared an announcement.
At the Annual General Meeting held on May 8, 2025, Swedish Orphan Biovitrum AB (Sobi) shareholders approved several key resolutions. These included the adoption of financial statements, re-election of board members, and the implementation of long-term incentive programs. The AGM also authorized the board to issue new shares and convertible bonds, enhancing Sobi’s capacity for future growth and strategic initiatives.
More about Swedish Orphan Biovitrum AB
Sobi is a global biopharmaceutical company focused on developing innovative treatments for rare diseases. With approximately 1,900 employees across various regions including Europe, North America, the Middle East, Asia, and Australia, Sobi reported a revenue of SEK 26 billion in 2024. The company’s shares are listed on Nasdaq Stockholm.
Average Trading Volume: 366,267
Current Market Cap: SEK102.1B
See more data about SOBI stock on TipRanks’ Stock Analysis page.